165 related articles for article (PubMed ID: 37851459)
21. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
[TBL] [Abstract][Full Text] [Related]
22. Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review.
Egeberg A; Linsell L; Johansson E; Durand F; Yu G; Vañó-Galván S
Dermatol Ther (Heidelb); 2023 Dec; 13(12):2951-2991. PubMed ID: 37833617
[TBL] [Abstract][Full Text] [Related]
23. Complementary therapies for acne vulgaris.
Cao H; Yang G; Wang Y; Liu JP; Smith CA; Luo H; Liu Y
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD009436. PubMed ID: 25597924
[TBL] [Abstract][Full Text] [Related]
24. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis.
Bechman K; Subesinghe S; Norton S; Atzeni F; Galli M; Cope AP; Winthrop KL; Galloway JB
Rheumatology (Oxford); 2019 Oct; 58(10):1755-1766. PubMed ID: 30982883
[TBL] [Abstract][Full Text] [Related]
25. Short-term efficacy and safety of biologics and Janus kinase inhibitors for patients with atopic dermatitis: A systematic review and meta-analysis.
Chen Q; Cui L; Hu Y; Chen Z; Gao Y; Shi Y
Heliyon; 2023 Nov; 9(11):e22014. PubMed ID: 38034798
[TBL] [Abstract][Full Text] [Related]
26. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis.
Alves C; Penedones A; Mendes D; Batel Marques F
Eur J Clin Pharmacol; 2022 Dec; 78(12):1923-1933. PubMed ID: 36207461
[TBL] [Abstract][Full Text] [Related]
27. Effect of JAK Inhibitors on the Risk of Death in Patients with Moderate to Severe COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Kow CS; Ramachandram DS; Hasan SS
Can J Hosp Pharm; 2024; 77(2):e3493. PubMed ID: 38868321
[TBL] [Abstract][Full Text] [Related]
28. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease.
Ma C; Lee JK; Mitra AR; Teriaky A; Choudhary D; Nguyen TM; Vande Casteele N; Khanna R; Panaccione R; Feagan BG; Jairath V
Aliment Pharmacol Ther; 2019 Jul; 50(1):5-23. PubMed ID: 31119766
[TBL] [Abstract][Full Text] [Related]
29. JAK inhibitors and psoriatic arthritis: A systematic review and meta-analysis.
Campanaro F; Batticciotto A; Zaffaroni A; Cappelli A; Donadini MP; Squizzato A
Autoimmun Rev; 2021 Oct; 20(10):102902. PubMed ID: 34274542
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: A multicenter retrospective study.
Avallone G; Mastorino L; Tavoletti G; Macagno N; Barei F; Schena D; Rossi M; Magnaterra E; Antonelli F; Babino G; Viola R; Gargiulo L; Conforti C; Rapparini L; Errichetti E; Patruno C; Ruggiero P; Roccuzzo G; Maronese CA; Girolomoni G; Gola M; Chiricozzi A; Balato A; Ambrogio F; Narcisi A; Zalaudek I; Gurioli C; Napolitano M; Marzano AV; Foti C; Costanzo A; Piraccini BM; Ferrucci SM; Ortoncelli M; Quaglino P; Ribero S
J Am Acad Dermatol; 2024 May; 90(5):1031-1034. PubMed ID: 38199282
[No Abstract] [Full Text] [Related]
31. The efficacy of Janus kinase inhibitors in patients with atopic dermatitis: A systematic review and network meta-analysis.
Zhang L; Wang L; Jiang X
Dermatol Ther; 2021 Sep; 34(5):e15098. PubMed ID: 34392600
[TBL] [Abstract][Full Text] [Related]
32. Analysis of the association between Janus kinase inhibitors and malignant skin tumors using the Food and Drug Administration Adverse Event Reporting System.
Liu T; Gao R; Li L; Wu B; Wu F
Int J Clin Pharm; 2023 Dec; 45(6):1483-1491. PubMed ID: 37606843
[TBL] [Abstract][Full Text] [Related]
33. Switching between JAK Inhibitors in Patients with Atopic Dermatitis: Unanswered Questions in Daily Clinical Practice.
Mastraftsi S; Bakakis M; Tsiogka A; Afroditi Kleidona I; Gregoriou S
Acta Dermatovenerol Croat; 2023 Dec; 31(3):162-164. PubMed ID: 38439732
[TBL] [Abstract][Full Text] [Related]
34. Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis.
Wood H; Chandler A; Nezamololama N; Papp K; Gooderham MJ
Int J Dermatol; 2022 Jun; 61(6):746-754. PubMed ID: 34423443
[TBL] [Abstract][Full Text] [Related]
35. Laboratory Monitoring During Isotretinoin Therapy for Acne: A Systematic Review and Meta-analysis.
Lee YH; Scharnitz TP; Muscat J; Chen A; Gupta-Elera G; Kirby JS
JAMA Dermatol; 2016 Jan; 152(1):35-44. PubMed ID: 26630323
[TBL] [Abstract][Full Text] [Related]
36. Janus Kinase Inhibitors and Risk of Venous Thromboembolism: A Systematic Review and Meta-analysis.
Bilal J; Riaz IB; Naqvi SAA; Bhattacharjee S; Obert MR; Sadiq M; Abd El Aziz MA; Nooman Y; Prokop LJ; Ge L; Murad MH; Bryce AH; McBane RD; Kwoh CK
Mayo Clin Proc; 2021 Jul; 96(7):1861-1873. PubMed ID: 33840525
[TBL] [Abstract][Full Text] [Related]
37. Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.
Sung YK; Lee YH
J Clin Pharm Ther; 2021 Aug; 46(4):984-992. PubMed ID: 33600008
[TBL] [Abstract][Full Text] [Related]
38. Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis.
Khoo JK; Barnes H; Key S; Glaspole IN; Östör AJ
Rheumatology (Oxford); 2020 Sep; 59(9):2217-2225. PubMed ID: 32406509
[TBL] [Abstract][Full Text] [Related]
39. Janus kinase inhibitors for hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials.
Lan SH; Wang CK; Chang SP; Lu LC; Hung SH; Lin WT
Expert Rev Anti Infect Ther; 2022 May; 20(5):773-779. PubMed ID: 34743661
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
